Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

5,370 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First Remission.
Wei AH, Döhner H, Pocock C, Montesinos P, Afanasyev B, Dombret H, Ravandi F, Sayar H, Jang JH, Porkka K, Selleslag D, Sandhu I, Turgut M, Giai V, Ofran Y, Kizil Çakar M, Botelho de Sousa A, Rybka J, Frairia C, Borin L, Beltrami G, Čermák J, Ossenkoppele GJ, La Torre I, Skikne B, Kumar K, Dong Q, Beach CL, Roboz GJ; QUAZAR AML-001 Trial Investigators. Wei AH, et al. Among authors: dong q. N Engl J Med. 2020 Dec 24;383(26):2526-2537. doi: 10.1056/NEJMoa2004444. N Engl J Med. 2020. PMID: 33369355 Clinical Trial.
Oral azacitidine preserves favorable level of fatigue and health-related quality of life for patients with acute myeloid leukemia in remission: results from the phase 3, placebo-controlled QUAZAR AML-001 trial.
Roboz GJ, Döhner H, Pocock C, Dombret H, Ravandi F, Jang JH, Selleslag D, Mayer J, Martens UM, Liesveld J, Bernal T, Wang MC, Yu P, Shi L, Guo S, La Torre I, Skikne B, Dong Q, Braverman J, Nehme SA, Beach CL, Wei AH. Roboz GJ, et al. Among authors: dong q. Haematologica. 2021 Dec 1;106(12):3240-3244. doi: 10.3324/haematol.2021.279174. Haematologica. 2021. PMID: 34551506 Free PMC article. Clinical Trial. No abstract available.
Extended dosing with CC-486 (oral azacitidine) in patients with myeloid malignancies.
Savona MR, Kolibaba K, Conkling P, Kingsley EC, Becerra C, Morris JC, Rifkin RM, Laille E, Kellerman A, Ukrainskyj SM, Dong Q, Skikne BS. Savona MR, et al. Among authors: dong q. Am J Hematol. 2018 Oct;93(10):1199-1206. doi: 10.1002/ajh.25216. Epub 2018 Sep 3. Am J Hematol. 2018. PMID: 30016552 Free PMC article. Clinical Trial.
Efficacy, safety and pharmacokinetics of subcutaneous azacitidine in Chinese patients with higher risk myelodysplastic syndromes: Results from a multicenter, single-arm, open-label phase 2 study.
Du X, Lai YY, Xiao Z, Liu T, Hu Y, Sun A, Li X, Shen ZX, Jin J, Yu L, Laille E, Dong Q, Songer S, Beach CL. Du X, et al. Among authors: dong q. Asia Pac J Clin Oncol. 2018 Jun;14(3):270-278. doi: 10.1111/ajco.12835. Epub 2017 Dec 28. Asia Pac J Clin Oncol. 2018. PMID: 29282890 Clinical Trial.
Initiating PeriCBD to probe perinatal influences on neurodevelopment during 3-10 years in China.
Wang YS, Su XT, Ke L, He QH, Chang D, Nie J, Luo X, Chen F, Xu J, Zhang C, Zhang S, Zhang S, An H, Guo R, Yue S, Duan W, Jia S, Yang S, Yu Y, Zhao Y, Zhou Y, Chen LZ, Fan XR, Gao P, Lv C, Wu Z, Zhao Y, Quan X, Zhao F, Mu Y, Yan Y, Xu W, Liu J, Xing L, Chen X, Wu X, Zhao L, Huang Z, Ren Y, Hao H, Li H, Wang J, Dong Q, Chen L, Huang R, Liu S, Wang Y, Dong Q, Zuo XN. Wang YS, et al. Among authors: dong q. Sci Data. 2024 May 7;11(1):463. doi: 10.1038/s41597-024-03211-5. Sci Data. 2024. PMID: 38714688
5,370 results